KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
网页链接CNBC2021-06-01
KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
网页链接免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。